Drug Patents Expiring in 2041

1. Drug name - DAPZURA RT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol Mar, 2041

(18 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/VIAL POWDER;INTRAVENOUS Prescription

2. Drug name - EPIDIOLEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160795 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus Mar, 2041

(18 years from now)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/ML SOLUTION;ORAL Prescription

3. Drug name - EXPAREL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033495 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes Jan, 2041

(18 years from now)

US11179336 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes Jan, 2041

(18 years from now)

Drugs and Companies using BUPIVACAINE ingredient

Treatment: Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia

Dosage: INJECTABLE, LIPOSOMAL;INJECTION

More Information on Dosage
Strength Dosage Availability
133MG/10ML (13.3MG/ML) INJECTABLE, LIPOSOMAL;INJECTION Prescription
266MG/20ML (13.3MG/ML) INJECTABLE, LIPOSOMAL;INJECTION Prescription

4. Drug name - NORLIQVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine Feb, 2041

(18 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; norliqva is indicated for the symptomatic treatment of chronic stable angina; norliqva is indicated for the treatment of confirmed or suspected vasospastic angina

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.